Opens profile photo
Follow
Jobie Budd
@jobiebudd
Data scientist interested in digital public health and AI-enabled diagnosis. Previously 🏳️‍🌈
London, Englandlinktr.ee/jobiebuddJoined January 2015

Jobie Budd’s Tweets

Pinned Tweet
1/ New paper, in the very first issue of ! We review the lessons learned for lateral flow test design and deployment for #COVID-19, and review how new technologies could allow affordable and rapid testing for a wider range infections
1
81
Show this thread
Being interdisplinary is odd sometimes. To mathematicians+computer scientists I am "the biologist/clinician". To molecular biologists and clinicians I am "the statistician". I am both excited about the science I span and also fearful of being accused of being a fraud everywhere.
7
205
Show this thread
Fantastic to see our paper on the history, state of the art, & exciting future of lateral flow devices particular for accessible global health come out today in ! It was a fun, interdisciplinary collaboration with ! Let me know what you think!
Quote Tweet
Lateral-flow tests provide a key technology in improving global health. Rachel McKendry and colleagues discuss the lessons learned from COVID-19 for the design of next-generation lateral-flow tests @McKendryLab @EricTopol @jobiebudd go.nature.com/3XkZU7K
8
6/ We recommend that diagnostic research & development is better funded, and prioritised alongside vaccines & therapeutics, so that we can better track & treat future disease outbreaks – particularly for diseases of epidemic potential – imagine a for diagnostics!
1
19
Show this thread
5/ Advances in molecular sensing, material science, and the ability to read or report results on smartphones could unlock the capability of the tried-and-tested lateral flow platform for a range of other use cases and healthcare pathways, such as antimicrobial resistance testing
Image
1
18
Show this thread
4/ COVID rapid tests were developed fast, especially compared to tests for other infections (see comparison to malaria tests below), but in future they could be deployed even faster and save more lives with investment in regional biobanks and the harmonization of regulation.
Image
1
17
Show this thread
3/ Ultimately, lateral flow tests were a powerful tool in interrupting chains of COVID transmission. But only 0.4% of the 3 billion COVID-19 tests performed through to mid-2022 were conducted in low-income regions, constraining our collective ability to respond to the pandemic.
Image
1
23
Show this thread
2/ The success of COVID-19 antigen LFTs can be in part attributed to the pathophysiology of SARS-CoV-2, that is, its short incubation period and high transmission rates, which are well suited to rapid, frequent testing
Image
2
33
Show this thread
Great to see our research out there! Wonderful team work from all - to name just a few. Thanks to team for this great collaboration. And support from and
Quote Tweet
Technologies that offer to diagnose #COVID-19 by coughing into a smartphone or tablet are no more effective at diagnosing the disease than checking for key #symptoms. Read more about our study with @UKHSA and @RoyalStatSoc: ow.ly/y0qU50M70N6
11
🧬➡️🩻I'm pivoting from biosensing and infectious diseases to medical imaging in the new year - what are some must-read AI in medical imaging papers?
1
3